Cellvizio
Device
Mauna Kea Technologies, Inc.
Total Payments
$153,800
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $153,800 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $153,800 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Confocal laser endomicroscopy as an imaging biomarker (CLIMB study) for the diagnosis of pancreatic cystic lesions | Mauna Kea Technologies, Inc. | $115,000 | 0 |
| nCLE For Diagnosis Of Peripheral Lung Nodules By Robotic Navigational Bronchoscopy | Mauna Kea Technologies, Inc. | $27,000 | 0 |
| Endomicroscopic Determinants or Relapse in Inflammatory Bowel Disease | Mauna Kea Technologies, Inc. | $11,800 | 0 |
Top Doctors Receiving Payments for Cellvizio
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Columbus, OH | $153,800 | 4 |
Ad
Manufacturing Companies
- Mauna Kea Technologies, Inc. $153,800
Product Information
- Type Device
- Total Payments $153,800
- Total Doctors 0
- Transactions 4
About Cellvizio
Cellvizio is a device associated with $153,800 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Mauna Kea Technologies, Inc..
Payment data is available from 2020 to 2020. In 2020, $153,800 was paid across 4 transactions to 0 doctors.
The most common payment nature for Cellvizio is "Unspecified" ($153,800, 100.0% of total).
Cellvizio is associated with 3 research studies, including "Confocal laser endomicroscopy as an imaging biomarker (CLIMB study) for the diagnosis of pancreatic cystic lesions" ($115,000).